Operation Warp Speed Spreads Its Bets With $1.6bn Novavax Deal

Biggest Award Yet, But Strategy Remains Unclear

Novavax has progressed into Phase I trials with relatively little funding, but backing from Operation Warp Speed makes it a stronger contender.

Novavax
Novavax's recombinant protein nanoparticle vaccine offers an alternative approach to Moderna and AstraZeneca

Novavax, Inc.’s efforts to develop a COVID-19 vaccine have received a huge boost from the US government’s Operation Warp Speed via a $1.6bn award.

The company had been one of a number of smaller companies chasing the leaders in the race to develop a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip